Compare Sana Biotechnology Inc (SANA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vale SA — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: Vale SA is far larger — about 68.5× Sana Biotechnology Inc's market cap, and Vale SA pays a 8.87% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vale SA for 109 Days on average.
| SANA | VALE | |
|---|---|---|
Market Cap | $836.71M | $57.32B |
Volume | 4,507,444 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $17.82 |
52-Week Low | $2.68 | $10.75 |
Typical Hold Time | 23 Days | 109 Days |
Enterprise Value | $749.96M | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
VALE stock trades at $13.42, down 1.4% on the day, reflecting recent pressure from earnings misses and sector-wide declines in steel producers. The technical outlook is bearish, with price near key support at $13, while fundamentals show declining net income margins and profit compression amid rising costs. Recent news highlights concerns over iron ore pricing and U.S. steel expansion plans impacting sentiment.
The investment case is mixed: analyst consensus leans Hold with a $16.21 price target, suggesting modest upside, but risks include cyclical commodity exposure, Brazilian regulatory issues, and margin pressure. Base metals growth offers a partial offset, but earnings consistency remains a challenge for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
